Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 2/20 | 0.48 |
| ▸ | SKP1 | P63208 | 2/20 | 0.48 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.41 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.41 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.41 |
| ▸ | DTYMK | P23919 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12986163 | 0.83 | CKS1B (0.45) | CKS1BSKP1SKP2PDE10APOLB | |
| SCHEMBL2358714 | 0.82 | CKS1B (0.42) | CKS1BSKP1SKP2PDE10APOLB | |
| SCHEMBL7521558 | 0.80 | CKS1B (0.54) | CKS1BSKP1SKP2PDE10APOLB | |
| SCHEMBL1065862 | 0.78 | CKS1B (0.51) | CKS1BSKP1SKP2PDE10APOLB | |
| SCHEMBL1063937 | 0.78 | CKS1B (0.48) | CKS1BSKP1SKP2PDE10APOLB | |
| SCHEMBL13437111 | 0.76 | HTR1A (0.52) | CKS1BSKP1SKP2POLBGPR119 | |
| SCHEMBL1048457 | 0.75 | POLB (0.55) | CKS1BSKP1SKP2POLBGPR119 | |
| SCHEMBL27340911 | 0.75 | GPR119 (0.70) | CKS1BSKP1SKP2PDE10APOLB | |
| SCHEMBL3624074 | 0.74 | KIT (0.49) | CKS1BSKP1SKP2PDE10APOLB | |
| SCHEMBL13437110 | 0.74 | HTR1A (0.56) | CKS1BSKP1SKP2POLBGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2349273-B1 | MODULATORS OF CXCR7 | CHEMOCENTRYX INC (US) | 2015-04-08 | — | — | EP | disclosed |
| EP-2349273-B1 | MODULATORS OF CXCR7 | CHEMOCENTRYX INC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8853202-B2 | Modulators of CXCR7 | CHEMOCENTRYX, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8288373-B2 | Modulators of CXCR7 | CHEMOCENTRYX, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288373-B2 | Modulators of CXCR7 | CHEMOCENTRYX, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288373-B2 | Modulators of CXCR7 | CHEMOCENTRYX, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2349273-A1 | MODULATORS OF CXCR7 | ChemoCentryx, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20110014121-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| US-20110014121-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| US-20110014121-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| US-20100311712-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311712-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311712-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100150831-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100150831-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100150831-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2010054006-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010054006-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014121-A1 | MODULATORS OF CXCR7 | CXCR1, CXCR5, CCR7 | CKS1B 2914/4885SKP1 3038/4885SKP2 4201/4885 |
| US-20100311712-A1 | MODULATORS OF CXCR7 | CXCR1, CXCR5, CCR7 | CKS1B 2914/4885SKP1 3038/4885SKP2 4201/4885 |
| US-20100150831-A1 | MODULATORS OF CXCR7 | CXCR1, CXCR5, CCR7 | CKS1B 2914/4885SKP1 3038/4885SKP2 4201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.